By Matteo Castia


Shield Therapeutics PLC said Monday that competitor Teva Pharmaceutical Industries Ltd. has withdrawn all its oppositions against the company's patents.

"Teva has withdrawn both its appeal against the European Patent Office's decision with regard to Shield's patent number 2668175, which covers a 'process for preparing an iron hydroxypyrone' and their opposition with regard to Shield's patent number 3160951 which covers 'crystalline forms of ferric maltol," the pharmaceutical company said.

This means that both patents are maintained and will continue to provide protection, Shield said.


Write to Matteo Castia at


(END) Dow Jones Newswires

October 19, 2020 02:59 ET (06:59 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.